AstraZeneca to Acquire TeneoTwo in Deal Worth Up to $1.26 Billion

AstraZeneca’s acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.